p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma

Journal of Urology

Volumn 173, Issue 3, 2005, Pages 725-728

  Shvarts, Oleg ^a   Seligson, David ^a   Lam, John ^a   Shi, Tao ^a   Horvath, Steve ^a   Figlin, Robert ^a   Belldegrun, Arie ^a   Pantuck, Allan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinoma, renal cell; Kidney; Neoplasm recurrence, local; Protein p53; Tumor markers, biological

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; GELSOLIN; KI 67 ANTIGEN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; VIMENTIN;

ADULT; AGED; CANCER STAGING; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MEDICAL RECORD; NEPHRECTOMY; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 13744253120     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000152354.08057.2a     Document Type: Conference Paper

References (20)

1. Skinner, D. G., Colvin, R. B., Vermillion, C. D., Pfister, R. C. and Leadbetter, W. F.: Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer, 28: 1165, 1971
2. Tsui, K.-H., Shvarts, O., Smith, R. B., Figlin, R. A., deKernion, J. B. and Belldegrun, A.: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol, 163: 1090, 2000
3. Amin, M. B., Amin, M. B., Tamboli, P., Javidan, J., Stricker, H., de-Peralta Venturina, M. et al: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol, 26: 281, 2002
4. Bui, M. H., Seligson, D., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y. et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res, 9: 802, 2003
5. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S. et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4: 844, 1998
6. Guinan, P., Sobin, L. H., Algaba, F., Badellino, F., Kameyama, S., MacLennen, G. et al: TNM staging of renal cell carcinoma. Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80: 992, 1997
7. Fuhrman, S. A., Lasky, L. C. and Limas, C.: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol, 6: 655, 1982
8. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T. et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5: 649, 1982
9. Liao, S. Y., Brewer, C., Zavada, J., Pastorek, J., Pastorekova, S., Manetta, A. et al: Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol, 145: 598, 1994
10. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R. et al: Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA, 89: 12028, 1992
11. Kuerbitz, S. J., Plunkett, B., Walsh, W. V. and Kastan, M. B.: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA, 89: 7491, 1992
12. Lane, D. P. and Benchimol, S.: p53: oncogene or anti-oncogene? Genes Dev, 4: 1, 1990
13. Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M. et al: Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res, 60: 3655, 2000
14. Moch, H., Sauter, G., Moore, D., Mihatsch, M. J., Gudat, F. and Waldman, F.: p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol, 423: 329, 1993
15. Uhlman, D. L., Nguyen, P. L., Manivel, J. C., Aeppli, D., Resnick, J. M., Fraley, E. F. et al: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst, 86: 1470, 1994
16. Girgin, C., Tarhan, H., Hekimgil, M., Sezer, A. and Gurel, G.: p53 mutations and other prognostic factors of renal cell carcinoma. Urol Int, 66: 78, 2001
17. Hofmockel, G., Wittmann, A., Dammrich, J. and Bassukas, I. D.: Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res, 16: 3807, 1996
18. Kim, H., Seligson, D., Liu, X., Janzen, N., Bui, M. H., Yu, H. et al: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res, 10: 5464, 2004
19. Galban, S., Martindale, J., Mazan-Mamczarz, K., Lopez de Silanes, I., Fan, J., Wang, W. et al: Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinomas cells. Mol Cell Biol, 23: 7083, 2003
20. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R. et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst, 85: 53, 1993